×




Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) case study is a Harvard Business School (HBR) case study written by Jennifer A. Chatman. The Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) (referred as “Gio Immunology” from here on) case study provides evaluation & decision scenario in field of Strategy & Execution. It also touches upon business topics such as - Value proposition, Organizational culture.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) Case Study


University of California, Berkeley-Haas collectionThis case study provides the story of Jennifer Cook, Senior Vice President of the Immunology and Ophthalmology (GIO) business unit at Genentech who had worked hard with her team from 2010-2012 to develop a cohesive culture to tie together GIO's four brands, as she believed that culture fundamentally would drive the performance of her group and it was too important to leave to chance. In the process, she had faced a series of pressing questions such as how to bring her team together; what might affect the group's performance; what features of culture were at play; and what stood in the way of positive change? This case study provides students an opportunity to see first-hand what Cook and her team came up with and how they implemented a very successful culture change process. The (B) case allows students to discuss performance measurement and what the team should do next. Please note: this case also has a supplementary case available. The (B) supplement can be found using product number B5777.


Case Authors : Jennifer A. Chatman

Topic : Strategy & Execution

Related Areas : Organizational culture




Calculating Net Present Value (NPV) at 6% for Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10021092) -10021092 - -
Year 1 3444611 -6576481 3444611 0.9434 3249633
Year 2 3959986 -2616495 7404597 0.89 3524373
Year 3 3960396 1343901 11364993 0.8396 3325225
Year 4 3221933 4565834 14586926 0.7921 2552073
TOTAL 14586926 12651304




The Net Present Value at 6% discount rate is 2630212

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Internal Rate of Return
2. Payback Period
3. Net Present Value
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Gio Immunology have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Gio Immunology shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A)

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Strategy & Execution Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Gio Immunology often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Gio Immunology needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10021092) -10021092 - -
Year 1 3444611 -6576481 3444611 0.8696 2995314
Year 2 3959986 -2616495 7404597 0.7561 2994318
Year 3 3960396 1343901 11364993 0.6575 2604025
Year 4 3221933 4565834 14586926 0.5718 1842151
TOTAL 10435808


The Net NPV after 4 years is 414716

(10435808 - 10021092 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10021092) -10021092 - -
Year 1 3444611 -6576481 3444611 0.8333 2870509
Year 2 3959986 -2616495 7404597 0.6944 2749990
Year 3 3960396 1343901 11364993 0.5787 2291896
Year 4 3221933 4565834 14586926 0.4823 1553787
TOTAL 9466182


The Net NPV after 4 years is -554910

At 20% discount rate the NPV is negative (9466182 - 10021092 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Gio Immunology to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Gio Immunology has a NPV value higher than Zero then finance managers at Gio Immunology can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Gio Immunology, then the stock price of the Gio Immunology should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Gio Immunology should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

Understanding of risks involved in the project.

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A)

References & Further Readings

Jennifer A. Chatman (2018), "Genentech Immunology & Ophthalmology (GIO): Culture Change to Drive Business Results (A) Harvard Business Review Case Study. Published by HBR Publications.


SCD SWOT Analysis / TOWS Matrix

Consumer Cyclical , Appliance & Tool


Maoming Shihua A SWOT Analysis / TOWS Matrix

Energy , Oil & Gas - Integrated


Winbase Chemical A SWOT Analysis / TOWS Matrix

Transportation , Misc. Transportation


Hilton Food SWOT Analysis / TOWS Matrix

Services , Retail (Grocery)


Denox Environmental & Tech SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Magellan Gold SWOT Analysis / TOWS Matrix

Basic Materials , Gold & Silver


Agro Phos SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing